Management of 25-year-old G2P1L1, 7 weeks, Previous LSCS, Prior Postpartum Renal Vein + Ovarian Vein Thrombosis, Currently on Dabigatran 110 mg

Risk Assessment

• Prior pregnancy/postpartum-associated VTE (renal vein + ovarian vein thrombosis) — this is categorized as an estrogen/hormonal-associated VTE, placing her in the highest recurrence risk group
• Postpartum VTE recurrence risk without prophylaxis: ~6.5% (pooled cohort data)
• The postpartum period carries the highest risk window; antepartum risk is also elevated given a prior hormonal-associated thrombosis
• Thrombophilia workup should be performed (ideally off anticoagulation), if not already done — to stratify dose intensity

Step 1: Switch Dabigatran to LMWH IMMEDIATELY

• DOACs cross the placenta
• No adequate safety or efficacy data in human pregnancy
• Should be switched to LMWH before or as soon as pregnancy is confirmed

"These patients may be receiving oral direct thrombin inhibitors (e.g., dabigatran)... before pregnancy and should be switched... given the paucity of safety and efficacy data for these drugs in pregnancy." — Creasy & Resnik's Maternal-Fetal Medicine

"Oral DTI (dabigatran) and anti-Xa inhibitors... have been extensively studied in pregnancy and therefore should be avoided." — Rosen's Emergency Medicine

Step 2: Choose the Right Anticoagulant

Step 3: LMWH Dosing

• Doses frequently need upward adjustment as pregnancy progresses due to increased volume of distribution and renal clearance (85% of patients require dose increase — Barbour et al.)
• Consider checking anti-Xa levels (target 0.6–1.0 U/mL at 4 hours post-injection for twice-daily dosing) particularly given the seriousness of prior thrombosis, though ASH 2018 advises against routine monitoring for all
• Increase to twice-daily dosing if not already done after 20 weeks

Step 4: Thrombophilia Workup

• If not done: test for Factor V Leiden, Prothrombin gene mutation, Protein C, Protein S, Antithrombin III deficiency, Antiphospholipid antibodies (aPL), Lupus anticoagulant, anti-β2-glycoprotein
• Antiphospholipid syndrome (APS) is especially important — renal vein thrombosis + obstetric history raises suspicion
• If APS confirmed: adds low-dose aspirin (75–100 mg/day) to LMWH

Step 5: Antenatal Monitoring

• Consultant-led obstetric care (joint haematology/MFM team)
• Serial fetal growth scans (thrombophilia/APS associated with FGR, placental insufficiency)
• Watch for signs of recurrent thrombosis (flank pain, leg swelling, tachycardia)
• Previous LSCS: plan timing and mode of delivery carefully (elective repeat LSCS vs. TOLAC)

Step 6: Peripartum Management

• Stop LMWH 24 hours before planned delivery (therapeutic dose) or 12 hours before (prophylactic dose)
• Switch to IV UFH infusion if delivery is urgent (can be reversed with protamine)
• Neuraxial anaesthesia is safe if LMWH stopped ≥24 hours prior (for therapeutic dose)
• Resume LMWH 4–6 hours after vaginal delivery or 6–12 hours after caesarean, once haemostasis is confirmed

Step 7: Postpartum Anticoagulation

• Mandatory postpartum anticoagulation for at least 6 weeks (prior VTE is absolute indication per ASH 2018 and ACCP guidelines)
• Given the severity and unusual site of prior thrombosis (renal vein + ovarian vein), long-term anticoagulation postpartum (potentially indefinitely) should be discussed with haematology
• Once breastfeeding is established and if transitioning to oral agent is desired: warfarin (compatible with breastfeeding) or restart dabigatran/DOAC only after stopping breastfeeding (insufficient breastmilk safety data for DOACs)
• LMWH is also compatible with breastfeeding

Summary Checklist

Updated Management: APS-Suspected Pregnancy with Prior Postpartum Renal/Ovarian Vein Thrombosis

Reassessing the Clinical Picture

Critical Question: Does She Meet APS Criteria?

• Confirmed venous thrombosis (renal vein + ovarian vein) in the postpartum period

• Anti-β2GP1 was weakly positive on one occasion postpartum
• For APS diagnosis, anti-β2GP1 must be IgG or IgM in titers >99th percentile, confirmed on two occasions ≥12 weeks apart
• A single weakly positive result does not formally satisfy the laboratory criterion
• ANA positivity alone is not an APS criterion

"At the other end of the clinical spectrum are patients with a clinical presentation consistent with APS but in whom the aPL results might be interpreted as 'low-positive' or 'equivocal' — not meeting international laboratory criteria." — Creasy & Resnik's Maternal-Fetal Medicine

Step 1: Repeat Aps and Autoimmune Panel NOW (Urgently)

Step 2: Start Anticoagulation Immediately

From Creasy & Resnik's Table 65.3 — "APS with history of prior thrombosis, not on long-term anticoagulation: intermediate-dose or full-anticoagulation-dose LMWH and LDA"

Step 3: Add Low-Dose Aspirin (LDA)

• 75–100 mg orally daily, started now and continued throughout pregnancy
• Standard of care in APS pregnancy regardless of whether history is primarily thrombotic or obstetric
• Reduces placental thrombosis and risk of preeclampsia

Step 4: Consider Hydroxychloroquine (HCQ)

• Current guidelines (Creasy & Resnik) recommend considering HCQ addition in all APS pregnancies, especially if ANA positive / SLE suspected
• HCQ reduces aPL titres, reduces flares, reduces thrombosis risk, and is safe in pregnancy (Category C; extensive use in SLE pregnancy)
• Dose: 200–400 mg/day orally
• Discuss with rheumatology/MFM

Step 5: Rheumatology Referral

• Positive ANA + possible APS warrants rheumatology evaluation to:
  • Rule out or diagnose SLE (which significantly worsens prognosis)
  • Establish baseline organ function
  • Co-manage immunosuppression if needed
• If SLE is confirmed with APS: very high-risk pregnancy requiring tertiary care

Step 6: Risk-Stratified Fetal Surveillance

"Pregnancies in women with a history of thrombosis… are at increased risk for fetal death and early delivery for preeclampsia or placental insufficiency even with standard treatment." — Creasy & Resnik's

• Fetal growth restriction — serial scans from 24 weeks, every 4 weeks
• Preeclampsia — blood pressure monitoring each visit; uterine artery Doppler at 20–24 weeks
• Placental insufficiency — umbilical artery Doppler if growth restriction detected
• Stillbirth surveillance — reduced fetal movement protocols, CTG from 36 weeks

Step 7: SLE Flare and Renal Monitoring

• Prior renal vein thrombosis may have resulted in renal impairment
• Baseline: serum creatinine, eGFR, urine protein:creatinine ratio
• Monitor renal function each trimester — proteinuria may indicate lupus nephritis or preeclampsia
• ANA-positive patients: watch for SLE flare (rash, joint pain, haematological changes, renal deterioration)

Step 8: Peripartum Plan

• Elective repeat LSCS at 37–38 weeks (prior LSCS, high-risk pregnancy)
• Stop therapeutic LMWH 24 hours before planned surgery
• Resume LMWH 6–12 hours post-LSCS once haemostasis confirmed
• Transition to oral anticoagulation postpartum

Step 9: Postpartum Long-Term Anticoagulation

• This patient had APS-associated thrombosis at an unusual site — postpartum anticoagulation is indefinite per most guidelines
• If APS formally confirmed: long-term warfarin (INR 2–3) is standard for secondary prevention of thrombosis in APS
• DOACs (including dabigatran): not recommended in APS with thrombosis — a landmark trial (RE-ALIGN) showed dabigatran was inferior to warfarin for thrombotic APS; DOACs are specifically listed as contraindicated in APS in multiple guidelines
• During breastfeeding: warfarin and LMWH are both safe; DOACs should be avoided

Summary Table

Why NOT to restart Dabigatran (even postpartum in APS)